AI drug discovery company AQEMIA and Sanofi have entered a multi-year research collaboration to accelerate the research and development of small molecule drug candidates.
As part of the agreement, AQEMIA will receive an upfront payment and up to USD 140 million in milestone payments. Sanofi will be responsible for laboratory research, development, and commercial activities of the drug candidates.
The partnership will leverage AQEMIA's deep physics platform combined with GenAI and Sanofi’s global R&D expertise to accelerate the design of novel drug molecules for Sanofi’s selected therapeutic targets.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.